Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis

Table 3

DLQI scores in study group at baseline and after 12 weeks of regular treatment.

Type of study subjects	Pretreatment (baseline)	Posttreatment (after 12 weeks)	value
Total cases ( = 40)	14.45 ± 3.19	9.40 ± 6.52	0.0004
Patients having lesions at mixed sites ( = 8)	14.27 ± 2.66	8.33 ± 4.87	0.0001
Patients with lesions at unexposed sites ( = 32)	14.20 ± 5.01	11.20 ± 7.73	0.0587
Patients who achieved ≥75% PASI improvement ( = 8)	12.25 ± 3.06	4.00 ± 2.73	0.0001
Patients who achieved 50–75% PASI improvement ( = 16)	13.38 ± 2.83	5.75 ± 1.24	0.0001
Patients with <50% PASI improvement ( = 12)	16.5 ± 2.39	14.67 ± 4.41	0.1737
Patients reporting worsening of disease ( = 4)	16.00 ± 2.31	19.75 ± 2.63	0.0006